文拉法辛治疗躯体形式障碍的临床疗效和不良反应

目的观察文拉法辛治疗躯体形式障碍的临床疗效和不良反应。方法对68例躯体形式障碍患者随机分为2组,一组36例服用文拉法辛,另一组32例服用阿米替林,疗程6周,分别与治疗前及治疗后第1、2、4、6周末以临床总体量表(CGI-SI),症状自评量表(SCL-90)躯体化因子项目评定,并与治疗第1、2、6周末评定不良反应症状量表(TESS)。结果文拉法辛治疗组起效较快,不良反应较少较轻,疗效与阿米替林治疗组相仿。结论文拉法辛是治疗躯体形式障碍的安全有效药物。

Objective To observe the clinical efficacy and side effects of venlafaxine in the treatment of somatoform disorders. Methods 68 patients with somatoform disorders were randomly assigned to receive venlafaxine or amitriptyline for six weeks, the patients were measured with clinical global impression scale（CGI-SI）and somatization in symptom checklist 90（SCL-90）before treatment and at the 1st,2nd,4th,6th weekend after treatment,treatment emergent symptoms scale（TESS） was used to assess the side effects at the 1st,2nd,6th, weekend after treatment. Results Its clinical efficacy was similar for the two drugs, venlafaxine was rapid onset of action and good tolerance. Conclusion Venlafaxine is an effective and safe drug to the patients with somatoform disorders.